Download PDF
Thromb Haemost 1983; 50(03): 652-655
DOI: 10.1055/s-0038-1665279
Original Article
Schattauer GmbH Stuttgart

Anticoagulant Properties of Three Mucopolysaccharides Used in Rheumatology

F Bauer
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
P Schulz
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
G Reber
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
,
C A Bouvier
The Hemostasis Unit, Geneva University Hospital, and the University Medical Center, Geneva, Switzerland
› Author Affiliations
Further Information

Publication History

Received 22 September 1982

Accepted 30 June 1983

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Three mucopolysaccharides (MPS) used in the treatment of degenerative joint disease were compared to heparin to establish their relative potencies on 3 coagulation tests, the aPTT, the antifactor X a activity and the dilute thrombin time. One of the compounds, Arteparon®, was one fourth as potent as heparin on the aPTT, but had little or no influence on the 2 other tests. Further in vitro studies suggested that Arteparon® acted at a higher level than factor Xa generation in the intrinsic amplification system and that its effect was independent of antithrombin III. In vivo administration of Arteparon® confirmed its anticoagulant properties, which raises the question of the clinical use of this MPS.

Keywords

Heparin - Other mucopolysaccharides - Anticoagulation - Mode of action
 

  • References

  • 1 Jaques LB. Heparins: anionic polyelectrolyte drugs. Pharmacol Rev 1980; 31: 99-166
    PubMedSearch in Google Scholar
  • 2 Bach GL, Panse P, Zeiller P. Glykosaminoglykanpolysulfat (GAGS, Arteparon®) zur Basistherapie der Arthrose. Z Rheumatol 1977; 36: 269-274
    PubMedSearch in Google Scholar
  • 3 Thilo G. Etude de 35 cas d’arthrose traités par l’acide chondroïtine sulfurique. Schweiz Rundschau Med (Praxis) 1977; 66: 1696-1699
    PubMedSearch in Google Scholar
  • 4 Bjornsson TD, Nash BS, Schaten BS. The anticoagulant effect of chondroitin-4-sulfate. Clin Pharmacol Ther 1982; 31: 203
    PubMedSearch in Google Scholar
  • 5 Thomas DP, Michalski R, Lane DA, Johnson EA, Kakkar VV. A heparin analogue with specific action on antithrombin III. Lancet 1977; 1: 120-122
    PubMedSearch in Google Scholar
  • 6 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate (SP54) and heparin. I: mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
    PubMedSearch in Google Scholar
  • 7 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. II: effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
    PubMedSearch in Google Scholar
  • 8 Raby C. Un critère d’efficacité des traitements hépariniques. Ann Anesthesiol fr 1964; 5: 129-134
    PubMedSearch in Google Scholar
  • 9 Milstone JH. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941; 48: 109-116
    PubMedSearch in Google Scholar
  • 10 Flury W. Communiqué de l’OICM. Arteparon, effets non désirables Schweiz Arztz 1982; 63: 1345
    PubMedSearch in Google Scholar